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The experiments presented were all conducted in the laboratories 
of Dr. Michael Davis and Dr. Dorothy W. Gallager of Yale University 
and The Connecticut Mental Health Center. They represent a series of 
interrelated studies designed to evaluate the relationship between 
biochemistry and behavior. The first study in this series - Experiment 
1 in this thesis - was carried out during my senior year at Yale 
College. It was included in this thesis as it is the most economical 
way to provide background information necessary for the understanding 
of the later experiments. The second and third experiments are 
comprised of work done during the summer prior to my second year of 
medical school as well as in May and June prior to beginning the third 
year. Parts of this work were presenteed at National Meetings of the 
Society for Neuroscience - in Cincinatti in 1980 and in Minneapolis in 
1982. 
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ABSTRACT 
Spinal modulation of the acoustic startle response: 
behavioral, pharmacological and biochemical studies 
in the normal, supersensitive and desensitized animal. 
David Isaac Astrachan 
198-4 
A major v goal of psyohopharmacology is to understand at a 
cellular level how drugs interact with various chemical systems to 
affect behavior. To accomplish this a behavior is needed which is 
quantifiable, amenable to pharmacological manipulations and generated 
from a known neural circuit. The acoustic startle reflex of the rat 
is a quantifiable behavior sensitive to a wide variety of drugs which 
has its final central nervous system synapse in the lumbar spinal 
cord. Therefore, analysis of the biochemical effects of drugs infused 
into the spinal cord should provide a powerful tool for assessing the 
relationship between pharmacology, biochemistry and behavior. 
Direct administration of serotonin, norepinephrine, and their 
agonists into the subarachnoid space of the lumbar spinal cord 
(intrathecal infusion) produced a dose dependent increase in acoustic 
startle magnitude. The effects were specific since noradrenergic 
antagonists prevented the increase in startle caused by noradrenergic 
agonists but not by serotonin agonists while serotonin antagonists 
blocked the facilitation caused by serotonin agonists but not by 
noradrenergic agonists. In contrast neither dopamine nor its agonist 
had any effect on startle magnitude at any of the doses tested. The 
magnitude of the behavioral facilitation caused by alpha-1-agonists 
correlated highly with the degree of alpha-1-adrenoceptor occupation 
iii 

measured by ^H-prazosin binding in lumbar spinal tissue. The more 
receptors that were occupied, the greater the behavioral change 
observed. Intrathecal administration of the noradrenergic neurotoxin 
6-hydroxydopamine (6-OHDA) produced a 95? decrease in spinal 
norepinephrine and markedly enhanced the behavioral response to 
intrathecal noradrenergic agonists as well as the number of 
alpha-1-adrenoceptors (denervation supersensitivity). The correlation 
between the increased behavioral sensitivity to norepinephrine 
agonists and the increase in the number of alpha-1-adrenoceptors 
caused by 6-OHDA over time was 0.99. 
Prior intrathecal infusion of the alpha-1-noradrenergic agonist 
phenylephrine prevented the excitatory effects of subsequent alpha-1 
agonists infused 6 hours later on acoustic startle (behavioral 
desensitization). This desensitization was associated with a decrease 
in the number of alpha-1-adrenoceptor sites in the lumbar spinal 
cord. 
Taken together these data indicate that by analyzing biochemical, 
pharmacological and behavioral processes in a specific region of the 
central nervous system, extremely high correlations can be found 
between biochemical (binding parameters) and behavioral (changes in 
acoustic startle response) measures. Moreover, they indicate that 
this model system may be particularly suitable for addressing more 
subtle questions about receptor mechanisms and behavior in the 
vertebrate. Eventually this system can be used to analyze the 
relationship between intracellular events and behavior. 
i v 
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Introduction 
Psychopharmacology is a science that attempts to bridge the gap 
between the model systems approach of the basic scientist and the more 
global observations and theories of behavioral scientists. By the use 
of simple behaviors amenable to observational, biochemical, 
physiological and pharmacological analyses conclusions that are made 
can be tested directly with a minimum of confounding variables. A 
major goal of psychopharmacology is to understand at a cellular level 
how drugs interact with various chemical systems to affect behavior. 
The central nervous system relies on these chemicals -- 
neurotransmitters -- for interneuronal communication. Drugs, which 
may mimic or antagonize these endogenous transmitters, are used as 
tools for probing transmitter systems. The resultant behavioral 
changes that accompany drug administration offer clues to how 
neurotransmitters modulate behavior. The more one is able to 
specifically examine the mechanisms of drug action on neuronal systems 
with the tools offered by biochemistry, physiology and pharmacology 
the clearer the information possible regarding how drugs affect 
neuronal processes which ultimately affect behavior. 
Behaviors range in complexity with the simplest behaviors 
involving monosynaptic reflex arcs. The more simple the behavior the 
easier it should be to study. It is no wonder then that the most 
definitive work on the neuronal bases of drug action, 
neurotransmission and behavioral plasticity have been done in 
invertebrates, most specifically on the siphon withdrawal reflex of 
the Aplysia or sea slug (33). The first step in the endeavor was to 
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delineate the neural circuit mediating the behavior being measured. 
Following this it was possible to characterize the neurotransmitters 
modulating transmission along this circuit. Finally, it has been 
possible to begin to determine at a cellular level how changes 
produced by neurotransmitters at specific synaptic regions produce 
behavioral changes. Comparable levels of analysis have not yet been 
possible in intact vertebrate systems, primarily because few 
vertebrate behaviors are simple enough to have a neural circuit 
amenable to a similar kind of experimental analysis. 
The short latency acoustic startle reflex in the rat is one 
vertebrate behavior which seems to provide an ideal system for 
studying behavioral and pharmacological plasticity. The startle 
reflex has proven to be a useful measure for studying how drugs effect 
sensory-motor reactivity (13). Acoustic startle amplitude is highly 
dependent on the characteristics of the eliciting stimulus and this 
tight degree of stimulus control allows nonzero baselines to be 
established against which to test drugs as well as lesions or 
electrical brain stimulation. The entire primary neural circuit has 
been recently worked out and shown to be quite simple involving only 
four synapses within the central nervous system (20). These are 1) 
posteroventral cochlear nucleus to 2) the dorsal and ventral nuclei of 
the lateral lemniscus to 3) the nucleus reticularis pontis caudalis 
and finally to 4) lower motor neurons of the spinal cord. With the 
circuit now delineated it is possible to determine exactly where and 
even how drugs act within this pathway to alter neuro transmission and 
ultimately affect behavior. 
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Generally, it has been assumed that drug effects are mediated by 
the brain, once peripheral effects have been ruled out. However, like 
most behaviors studied in psychopharmacology the startle response 
ultimately involves spinal motor neurons for its expression. These 
spinal motor neurons are known to receive dense modulating input from 
neurons located in the brainstem (10,12,47) and the importance of the 
spinal cord in mediating behavioral drug effects has been demonstrated 
(49,69,71). Yaksh and co-workers have described a method that allows 
direct infusion (intrathecal administration) of compounds onto the 
spinal cord in waking rats (70) and have shown these compounds to 
remain localized about the tip of the catheter with negligible 
diffusion into other areas of the CNS. 
As the final synapse of the primary acoustic startle circuit 
occurs in the spinal cord it is now possible with the use of 
intrathecal catheters to infuse drugs directly onto a specific area of 
the central nervous systems involved in a specific and quantifiable 
behavior. It should also be possible to examine the area involved in 
the behavior by removing the tissue and biochemically determining at 
the cellular level how drugs interact with various neurotransmitter 
systems to affect behavior. The present series of experiments were 
designed towards this purpose. 
Experiment 1_: Spinal modulation of the acoustic startle response: the 
role of norepinephrine, serotonin and dopamine. 
Systemic administration of serotonin (5-HT) , norepinephrine (NE) 
or dopamine (DA) agonsits have been shown to increase both acoustic 
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and tactile startle (13). 5-Methoxydimethyltryptamine, a 5~HT 
agonist, given systemically produces large increases in acoustic 
startle magnitude (16). Combinations of drug which increase central 
nervous system levels of 5-HT such as L-tryptophan and pargyline (a 
monoamine oxidase inhibitor) also increase acoustic startle and this 
effect can be blocked by pretreatment with the 5~HT synthesis 
inhibitor p-chlorphenylalanine or by administration of varoius 5-HT 
antagonists (13). 
Most available data suggest that norepinephrine is excitatory to 
acoustic startle. Drugs that increase availability of central NE by 
blocking its reuptake, such as moderate doses of desipramine or 
chiordesipramine, increase acoustic startle (19). Conversely, 
depletion of NE by lesions of the NE-containing cell bodies in the 
locus coeruleus depresses both acoustic and tactile (1) startle. In 
addition, the alpha-1 adrenergic antagonist phenoxybenzamine depresses 
startle at doses known to block adrenergic receptors (35). NE may 
also help mediate the excitatory effects of high doses of amphetamine 
since pretreatment with phenoxybenzamine blocks the excitatory effects 
of 1-amphetamine (35) and pretreatment with the NE synthesis inhibitor 
FLA-63 blocks the excitatory effects of d-amphetamine (36). 
High doses of d- and 1-amphetamine in addition to releasing 
endogenous norepinephrine from nerve terminals also causes a marked 
release of dopamine. The excitatory effects of high dose amphetamine 
on acoustic startle is also blocked by pretreatment with the DA 
antagonists haloperidol or pimozide (35). Furthermore, the directly 
acting DA agonist apomorphine also increase acoustic startle and this 
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effect can be blocked by haloperidol or pimozide (14,35). The results 
of these systemic drug studies suport the idea that enhancement of DA 
transmission increases startle amplitude. 
Anatomical studies indicate that spinal motor neurons receive 
dense input from 5~HT, NE and DA containing neurons located in the 
brainstem (10,12,14). Single unit recording studies indicate that 
both 5-HT and NE facilitate excitation of motor neurons produced by 
afferent stimulation (39,68). This increase in excitability occurred 
without a direct increase in the firing of these motor neurons 
consistent with a role for NE and 5_HT as neuromodulators within the 
spinal cord. Behavioral studies indicate that 5-HT or NE facilitate 
spinal reflexes in spinalized or decerebrate animals (2,3,40,52). 
Thus, it is possible that the excitatory effects on startle produced 
by systemic administration of monoamine agonists result from a direct 
modulatory action in the spinal cord. 
Using a modification of the intrathecal technique developed by 
Yaksh and his coworkers the present experiments were designed to test 
the effects of intrathecal administration of 5~HT, ME, DA, and their 
agonists on the acoustic startle reflex. 
Subj ects 
Male Sprague-Dawley, Charles River rats (350-450 g) were used in 
this and all subsequent experiments. Rats were housed in group cages 
(4-5 per cage) until intrathecal implantation at which time they were 
then housed singly. They were kept in a colony room with a reverse 
light-dark cycle (12h-12h). Food and water were continously 
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available. 
Preparation of the Animals: Catheter Implantation 
Animals were anesthetized with halothane and positioned with 
blunt ear bars in a Kopf stereotaxic instrument. The cisterna magna 
was exposed and the overlying membrane punctured. An 8.5~cm length of 
polyethylene tubing (PE 10) fused to a 3«5~cm length of PE-20 tubing 
was inserted into the cisterna magna and gently "snaked" down over the 
spinal cord to terminate above the lumbar enlargement as described by 
Yaksh and Rudy (70). The PE 20 portion of the catheter was secured 
between wound clips used to close the incision. The catheter was then 
filled with sterile saline and the rats allowed to recover for 1 week. 
For animals housed longer than four weeks with chronic catheters a 
slight modification of the implantation procedure was used (37). This 
involved drilling a small hole through the occipital and parietal 
bones of the skull and placing the PE 20 part of the catheter through 
these holes. This firmly anchored the catheter and prevented its 
accidental removal that frequently occurred in animals housed for more 
than four weeks catheterized in the usual way. 
Measurement of acoustic startle amplitude. 
Five separate stabilimeter devices were used to record the 
amplitude of the startle response. Each stabilimeter consisted of an 
8x15x15 Plexiglass and wire mesh cage suspended within a 25 x 20 x 
20 cm steel frame. Within this frame, the cage was sandwiched between 
four compression springs above and a 5 x 5 cm rubber cylinder below 
with an accelerometer (MB Electronics type 302) located between the 
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bottom of the cage and the top of the rubber cylinder. Cage movement 
resulted in displacement of the accelerometer and the resultant 
voltage was fed through a matched accelerometer amplifier (MB 
Electronics model N 504), the output of which was proportional to the 
velocity of accelerometer displacement. 
The amplified signal then was fed to a specially designed 
sample-and-hold circuit. Basically, this current consisted of five 
channels, one for each stabilimeter, and was used to sample the peak 
accelerometer voltage that occurred during a 20-msec time band 
immediately after the onset of the startle-eliciting stimulus. 
Immediately prior to this sample period, each channel was discharged 
so that any spontaneous activity occurring between stimulus and stored 
in one of each of the five channels. Immediately after the sample 
period, the output of each of the five channels was digitized through 
a specially designed analog-to-digital convertor and fed into a PDP-11 
computer. Startle amplitude could vary from 0 to 160, allowing 
appreciable resolution among various startle amplitudes. 
The five stabilimeters were located in a 2.5 x 2.5 x 2 m, dark, 
ventilated, sound-attenuated chamber (Industrial Acoustic Co., IAC). 
They were placed 1.1 meters from an Altec high frequency loudspeaker, 
which was used to provide a 90-msec noise burst generated by a 
Grason-Stadler noise generator, amplified through an Altec 100-W power 
amplifier, and shaped through a Grason-Stadler electronic switch to 
have a rise-decay time of 5 msec. Background white noise provided by a 
Grason-Stadler white noise generator. The intensity of the noise 
burst (110 dB) and the background white noise (55 dB) was measured 
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with a General Radio model 1551-C sound level meter (A scale) by 
placing the microphone in each cage and positioning the cages to have 
comparable readings. 
Testing Procedure 
One week after implantation rats were placed in the stabi1imeters 
and 5 min later a program began which gave startle-eliciting tones 
every 20 sec for min. This constituted the pre-drug baseline. 
They were then removed from the test cages and infused with 18 ul of 
drug dissolved in sterile salilne (pH 7.4) at a rate of 5 ul/min. Ten 
ul of drug was actually delivered onto the spinal cord while the 
remaining 8 ul occupied the internal volume of the catheter. Right 
after infusion the rats were returned to test cages and immediately 
given tones every 20 sec for 1 hour. The post drug infusion scores 
for each rat were compared with their respective pre-drug baseline to 
determine the changes in startle amplitude following drug treatment. 
Rats were tested only once and then discarded. Following testing the 
catheters were removed and examined for possible leakage or clogging. 
Only results from animals with intact and unclogged catheters were 
included as data. 
Results 
Intrathecal administration of 100-200 ug of 5-HT (free base) 
increased startle by about 50$ immediately after administration, but 
the effect only lasted for a few minutes. Pretreatment with the 
monoamine oxidase inhibitor pargyline (25 mg/kg) 1 hour earlier 
markedly enhanced the excitatory effect of 5~HT. Following pargyline, 
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5-HT (6.25, 25 or 50 ug) caused a dose-dependent increase in startle 
that now lasted for 30-40 minutes at the highest dose. An overall 
analysis of variance using each animal's postinfusion minus 
preinfusion change scores revealed a dose-dependent increase in 
startle amplitude over these conditions, F (3/16) = 11.86 p < 0.001, 
that was linearly related to the log dose given, Flin (1/16) = 22.51, 
p < 0.001 . 
Intrathecal administration of the direct 5-HT agonist, 
5-methoxy-N,N-dimethyltryptamine (5-MeODMT) produced a marked and 
immediate increase in acoustic startle amplitude. The left panel of 
Fig. 1 shows the time course for the most effective dose (50 ug) 
relative to the saline condition. The right panel of Fig. 1 shows the 
dose-response curve expressed as the mean change from the preinfusion 
baseline to the first 10 min postinfusion + S.E.M. An overall 
analysis of variance using these change scores revealed a significant 
dose-response effect, F (3/8) = 11.44, p < 0.01, that was linearly 
related to the log dose used, Flin (1/18) = 30.17, p < 0.001. 
Intrathecal NE immediately increased acoustic startle, but the effects 
decayed very rapidly, within about 4 min. All doses of NE that were 
used (12.5, 25, 50, and 100 ug free base) showed similar effects: a 
rapid initial increase in startle followed by an immediate decay. 
Analyses of the postinfusion-preinfusion change scores for each animal 
revealed a significant effect of NE, F (1/15) = 11.56, p < .005. Over 
this dose range, however, a significant dose-response relationship was 
not obtained. 
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The left panel of Figure 2 shows the results of intrathecal 
infusion of 50 ug of the alpha-1 adrenergic agonist phenylephrine. 
Intrathecal phenylephrine increased startle amplitude for roughly 40 
min following infusion. This effect was directly related to the dose 
that was used, F (3/13) = 8.08, p < 0.001, as shown in the right panel 
of Figure 2. In contrast to the alpha-1 adrenergic agonist 
phenylephrine, intrathecal administration of the beta-adrenergic 
agonist isoproterenol did not alter acoustic startle at any of the 
doses tested (25, 100, or 400 ug). 
Table 1 shows the results of pretreating rats intraperitoneally 
with 5-HT or NE antagonists 15 minutes prior to the intrathecal 
infusion of either 5-MeODMT (50 ug) or phenylephrine (50 ug). A dose 
of 1.0 mg/kg of the alpha-1 adrenergic antagonist WB-4101 completely 
blocked phenylephrine’s effect on startle but not that of 5-MeODMT. 
In contrast, a dose of 1.0 mg/kg of the 5-HT antagonist cyproheptadine 
completely blocked the effect of intrathecal 5-MeODMT but not that of 
phenylephrine. On the other hand, the beta-antagonist propranolol did 
not block the increase in startle amplitude caused by either 5-Me0DMT 
or phenylephrine. 
The preceeding experiments demonstrate that either 5-HT or NE can 
increase acoustic startle when applied directly onto the spinal cord. 
Excitation following intrathecal 5-HT or 5~HT agonists appears to be 
mediated through a 5-HT receptor. In the present study the direct 
acting 5-HT agonist, 5-MeODMT, increased acoustic startle when applied 
intrathecally and this effect was blocked by systemic administration 
of the 5-HT antagonist, cyproheptadine, but not by the 
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TABLE 1 
Mean change in startle amplitude (± S.E.M.) from 0 to 20 minutes after 
intrathecal 5-MeODMT or phenylephrine following intraperitoneal admin¬ 
istration of either saline, the alpha-l-noradrenergic antagonist 
WB-4101, the 5-HT antagonist cyproheptadine or the beta-noradrenergic 
antagonist propranolol. 
All pretest drugs were given 15 minutes before intrathecal infusion of 
test drugs. Per cent change relative to preinfusion baseline is shown 
in parentheses. 
Pretest drug Test drug 
5-MeODMT (50ug) Phenylephrine (50ug) 
Saline 26.1 8.0 (+130%) 15.1 + 5.2 (+116%) 
WB-4101, 0.2mg/kg — 12.2 + 4.8 (+93%) 
WB-4101, l.Omg/kg 18.0 + 4.3 (+98%) -0.7 + 3.0 (-10%)** 
Cyproheptadine, 0.2mg/kg 9.0 + 4.6 (+37%) — 
Cyproheptadine, 1.Omg/kg -2.8 •+ 1.6 (-8%)** 15.1 ■4* 3.2 (+111%) 
Cyproheptadine, 5.Omg/kg -5.2 + 2.4 (-12%)** — 
Propranolol, 20mg/kg 20.5 ■+ 6.0 (+96%) 14.6 + 4.0 (+101%) 
**P^0.01 relative to saline 
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alpha-1-adrenergic antagonist WB-4101. Other work has shown that the 
increase in startle produced by intrathecal 5-HT is blocked by 
systemic administration of the 5~HT antagonist, cinanserin (17). 
Intrathecal NE appears to increase startle via stimulation of an 
alpha-1 receptor. Thus, the alpha-1 agonist phenylephrine increased 
startle when applied intrathecally and this effect was blocked by the 
alpha-1 antagonist WB-4101 but not by the beta-antagonist propranolol 
nor cyproheptadine. In contrast, intrathecal administration of the 
beta-agonist isoproterenol did not affect acoustic startle. In 
contrast to 5~HT and NE, neither DA nor the DA agonist apomorphine 
increased acoustic startle when given intrathecally. 
This experiment clearly demonstrates the importance of the spinal 
cord as a target for mediating drug effects on behavior. 
Experiment 2: Correlations between alpha-1 adrenergic stimulation of 
acoustic startle and alpha-1 adrenoceptor occupancy and number in rat 
lumbar spinal cord: supersensitivity vs normal state. For a drug to 
function it must be able to induce a change in a cellular system. One 
mechanism by which a drug alters neuronal function is by its joining 
with a specific recpetor on that cell. This drug-receptor complex may 
then lead to a change in cellular activity which may ultimately be 
expressed as a behavioral change. 
The functional consequences of alterations in neurotransmitter 
receptors is important for the study of the neurochemical basis of 
behavior. Recently, _in vitro high affinity binding of 
neurotransmitter substances to neuronal membranes has been used to 
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identify and characterize certain kinetic parameters of receptors such 
as affinity and number of recognition sites available for interaction 
with neurotransmitters or drugs (72). A relationship between 
alterations in neurotransmitter binding sites and behavior can be used 
to determine how binding parameters may relate to the functional state 
of the receptor (11). In order to make such a correlation a behavior 
is needed which is: 1) altered by specific pharmacological 
manipulations; 2) quantifiable; and 3) generated from a specific area 
of the CNS. 
As has been shown, the acoustic startle response satisfies these 
three criteria. It is quantifiable and has been shown to be altered 
by both noradrenergic and serotonergic agonists applied locally to a 
specific area of the CNS. Alpha-1-noradrenergic receptors have been 
localized in the spinal cord and a specific alpha-1 induced increase 
in cAMP has been found in this tissue. In addition intrathecal 
d-amphetamine, which acts indirectly to increase noradrenergic 
transmission, has also been shown to increase the amplitude of 
aocustic startle (15). The excitatory effects of d-amphetamine -- like 
those of phenylephrine — can be blocked by systemic administration of 
the alpha-1 antagonist, WB—4101, but not by the 5-HT antagonist 
cyproheptadine, or the dopamine antagonist haloperidol (15). 
The acoustic startle reflex provides, therefore, a test system in 
which quantifiable changes in behavior can be measured following 
pharmacological manipulations in a limited part of the central nervous 
system. Examination of the lumbar spinal tissue in rats given 
intrathecal infusions of alpha-1-adrenergic agonists should thus 
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provide a method to determine the parameters of alpha-1-adrenergic 
binding that may be important in mediating changes in behavioral 
output. 
Prazosin has been shown to have a preferential affinity for 
alpha-1-adrenoceptor sites both in the peripheral (9,41) and central 
nervous system (26,42,63). Hence, tritiated prazosin was used in 
these studies to evaluate the effects of various physiological and 
pharmacological manipulations on alpha-1-binding sites. 
Correlations between behavior and binding were made using two 
different approaches. The first series of studies evaluated if there 
would be a correlation within animals, between the increase in the 
acoustic startle response produced by intrathecal administration of an 
alpha-1-agonist with the number of 3H-prazosin binding sites occupied 
by that agonist. If the magnitude of the behavior is related to 
receptor occupation, then increases in binding should be correlated to 
increases in behavior. The second series of experiments involved 
altering the receptors themselves. 6-OHDA lesions have been shown to 
cause significant increases in the number of alpha-1-adrenoceptors 
(54,56,61,62). If these receptors are involved in mediating the 
behavioral response, then an increase in the number of binding sites 
following denervation should be associated with an enhancement of the 
behaviorial response produced by an alpha-1-agonist. Moreover, 
depending on the correlation between these two measures, it should be 
possible to determine from these data the relationship between 
receptor occupation and pharmacological efficacy in the normal and 
denervated state. 
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d-Amphetamine and Phenylephrine: Receptor Occupation and Startle 
Change Correlation 
One week following implantation rats were tested for acoustic 
startle following intrathecal administration of d-amphetamine or 
saline. Testing involved placing the rats in the stabilimeters and 5 
min later giving startle eliciting noise bursts every 20 sec for 14 
min to establish a pre-infusion baseline. Rats were then removed from 
the test cages and infused with 100 ug d-amphetamine dissolved in 10 
ul of sterile saline followed by 8 ul of sterile saline to flush the 
d-amphetamine solution from the catheter and to occupy the catheter's 
internal volume. Immediately following infusion rats were returned to 
test cages and given noise bursts every 20 sec for 30 min. Previous 
work has shown that d-amphetamine's maximal effect on startle occurs 
about 30 min after the drug is infused. At the end of the 30 min test 
session each rat was decapitated and a 2.5 cm section of the lumbar 
cord was dissected out, weighed and frozen. The decapitation and 
dissection procedure took approximately 2-3 min. Lumbar cord segments 
weighed 214 + 22 mg per animal. Tissues were stored at -70 °C until 
assayed. Preliminary experiments showed no significant difference in 
binding between fresh tissue and tissue frozen under those conditions 
for at least 3 weeks. Assays were completed within this time period. 
In a second group of rats the same procedures were repeated using 
phenylephrine as a direct alpha-1-adrenergic agonist instead of 
d-amphetamine. In addition, half the rats were treated with 6-OHDA to 
determine in a preliminary way if this would increase the 
effectiveness of phenylephrine and, if so, to determine the 
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correlation, within animals, between the response to phenylephrine and 
receptor binding in normal and denervated animals. To assure that the 
treatment groups would have similar initial startle amplitude prior to 
any treatment, all rats were placed in the stabilimeters and 5 min 
later presented with startle-eliciting noise bursts every 20 sec for 
10 min. Based on the mean startle amplitude for each animal, the rats 
were divided into two groups with each group having similar mean 
startle amplitudes and variances. All of the rats within one group 
then received 20 ug of 6-OHDA dissolved in 10 ul of 0.155 ascorbic 
acid; the other matched group received an equal volume of the vehicle 
(0.155 ascorbic acid). The pH of both solutions was adjusted to 5.4 
and the infusion rate was 10 ul/min. Following infusion the catheters 
were flushed with 8 ul of sterile saline. Thus, 10 ul of 6-OHDA or 
vehicle was actually delivered onto the spinal cord, while the 
remaining 8 ul of saline occupied the catheter's internal volume. 
Following infusion animals were returned to their home cages. 
Animals were tested one week after receiving either 6-OHDA or 
vehicle, using either 25 or 50 ug of phenylephrine which was infused 
after a 14 min pre-infusion baseline. After the infusion the rats 
were returned to test cages and given noise bursts every 20 sec for 30 
min. Experiment 1 showing phenylephrine's maximal effect on startle to 
occur from 15 to 30 min after the drug's infusion. At the end of the 
test session lumbar spinal cords were removed as described 
previously. 
3H-Prazosin Binding: In Vitro Estimation of Receptor Occupation 
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3H-prazosin binding assays were carried out as a slight 
modification of the assay described by Greengrass and Bremner (26). 
In these studies lumbar cord sections were homogenized (Polytron 
PT-10/setting 8 for 20 sec) in 40 volumes (w/v) of ice cold 50 mM 
Tris-HCl pH 8.0 (at 25 C). One half of the resulting homogenate was 
removed and stored on ice until assay. This sample was labeled the 
"unwashed fraction". The remaining homogenate was further diluted 
with 200 volumes (w/v) of cold Tris buffer (pH 7.4), resuspended and 
centrifuged at 42,000 x g for 10 min; the resulting membrane pellet 
was resuspended and centrifuged two additional times. Preliminary 
experiments indicated that washing the membrane pellet three times was 
sufficient to remove residual phenylephrine from the assay which may 
have interfered with the binding of 3H-prazosin. Membranes were 
finally resuspended in 40 volumes (w/v) of 50 mM Tris-HCl buffer, (pH 
8.0), labelled the "washed fraction". Aliquots (0.8 ml) of both the 
"washed" and "unwashed" fractions were incubated in the presence of 
ascorbic acid (0.1$), and single concentration of (0.7 to 1.0 nM) 
3H-prazosin (Amersham-Searle S.A. 20.2 Ci/mM) and 0.05 M Tris HC1 
buffer (pH 8.0) to 1 ml total volume. Assays were analyzed in 
triplicate, two additional assay tubes contained 1 uM WB-4101 (WB 
Pharmaceuticals) to determine non-specific binding. Incubations were 
carried out at room temperature for 30 min; after incubation the 
samples were rapidly filtered through GF/B filters (Whatham Co., U.K.) 
under low vacuum. The filters were washed with three 8 ml aliquots of 
ice-cold 50 mM Tris buffer (pH 7.4) and counted in a liquid 
scintillation counter in 8 ml Econofluor (New England Nuclear). 
Results are reported as specific prazosin binding per mg protein, by 
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the method of Lowry et al. (14) representing total binding minus 
binding in the presence of 1 uM WB-4101. Each animal had a specific 
"unwashed" SB(UW) binding score and a specific "washed" SB(W) binding 
per mg protein score. An index of recept or 
was calculated as the diff erence between the 
specific binding of 3H -prazosin. Percent of 
was determined by the formula % occupied: 
SB(W) - SB(UW) 
x 100 
Bmax 
Phenylephrine Dose Response Curve Following 6-OHDA 
One week following implantation, a total of 48 animals were 
matched into four groups using the methods described above. Half the 
rats in each group were lesioned with 20 ug of intrathecal 6-OHDA, 
while the other half received an equal volume of vehicle. One week 
later animals were placed in the test cages and a preinfusion baseline 
was established. The animals were then removed from the test cages 
and received either saline, 12.5, 25, or 50 ug of phenylephrine, 
intrathecally. Immediately following infusion rats were returned to 
test cages and given noise bursts every 20 sec for 30 min. They were 
then discarded. 
6-OHDA Time Course: Receptor Change, Startle Change Correlation 
Animals were implanted and matched into two groups as described 
before. One group received 20 ug of 6-OHDA in 10 ul of 0.1% ascorbic 
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acid while the other matched group received an equal volume of 
vehicle. At various time intervals following the infusions (3 days, 
1, 2, or 4 weeks) both vehicle and 6-OHDA groups were tested for 
acoustic startle following intrathecal administration of 12.5 ug of 
the alpha-1 -agonist phenylephrine. This involved the same procedure 
of establishing a preinfusion baseline, removing the animals from the 
test cages, infusing all of them with 12.5 ug of phenylephrine and 
then returning them to the test cages for 30 min of startle eliciting 
noise bursts. Following testing lumbar cords were removed and 
prepared for the 3H-prazosin binding assay. 
Scatchard Analysis 
At specific times after 6-OHDA or vehicle administration and 
subsequent phenylephrine testing (3 days, 1, 2, or 4 weeks) animals 
were killed and lumbar spinal cord tissues for each treatment group 
were pooled . Pooled tissues were homogenized in cold 1: 200 (w/v) of 
Tris HC1 buffer (pH 7.4), centrifuged at 42,000 x g for 10 min, 
resuspended and centrifuged two additional times. The resulting 
washed membrane pellets were resuspended in cold 1:40 (w/v) 50 mM Tris 
HC1 buffer (pH 8.0). Aliquots (0.8 ml) of this homogenate were 
assayed for 3H-prazosin binding as described above in the presence of 
varying concentrations of 3H-prazosin (0.05 to 2.0 nM). Non-specific 
binding was assessed by the addition of 1 uM WB-4101. Quadruplicate 
samples and duplicate non-specific binding values were obtained for 
each concentration of 3H-prazosin. The maximum number of binding 
sites (Bmax) and apparent dissociation constant (KD) were estimated by 
Scatchard analysis. Protein concentrations were determined by the 
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method of Lowry et al. (38). 
Determination of the Ki: Phenylephrine Competition 
Pooled tissue for 6-OHDA lesioned and vehicle treated animals 
were analyzed for 3H-prazosin binding and its ability to be displaced 
by the _in vitro addition of various concentrations of phenylephrine. 
Washed lumbar cord membranes were prepared as described above and 
incubated in the presence of 1 nM 3H-prazosin and various 
concentrations of phenylephrine (1 x 10-3 M to 1 x 10-6 M) in the 
presence or absence of 1 uM WB-4101. 
Determination of Norepinephrine Content 
Biochemical assay for catecholamines were performed using ligand 
chromatography with electron detection as described by Reinhard and 
Roth (50). Briefly, tissue samples (ca. 20 mg, wet weight) were 
sonically disrupted in 400 ul of 0.1 M perchloric acid containing 0.23 
mM ascorbic acid (as an anti-oxidant), 75 nM dihydroxybenzyl amine; 
(Aldrich Chemical Co., Milwaukee, WI). The homogenates were 
centrifuged at 25,000 x g x 15 minutes and 300 ul aliquots of the 
clear supernatants were retained for subsequent analysis. 
The supernates were adjusted to pH 8.6 and applied to miniature 
alumina columns (containing approximately 20 mg of acid-washed 
aluminum oxide). Passage of fluid through the columns was facilitated 
by centrifuging the columns (suspended in the mouths of 10 x 75 mm 
test tubes) at 50 x g x 2 min. The columns were washed with water 
(which was discarded) and eluted with 120 ul of 0.1 M oxalic acid; 50 
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ul of the eluate were applied to the LC for catechol analysis. 
The chromatographic conditions for the model 420 Altex LC 
(equiped with a Bioanalytical System Inc., LC-3 amperometric detector) 
was as follows: the mobile phase was a 0.1 M NaPhosphate buffer (pH 
3.2) which contained 0.2 mM octane sulfonic acid) (Regis Chemical Co., 
Morton Grove, IL), 0.1 mM ethylenediaminetetraacetic acid (EDTA), and 
4$ (v/v) methanol; a flow rate of 1.5 ml/min was used through an Altex 
Ultrasphere - i.p. column. Compunds were identified on the basis of 
retention time and were quantitatively compared to authentic 
standards, run the same day. 
RESULTS 
The correlation between the increase in startle caused by 100 ug 
of intrathecal d-amphetamine and the 3H-prazosin binding sites 
occupied is shown in Figure 3. Occupation of binding sites was 
defined as the "washed" minus "unwashed" specific 3H-prazosin binding 
values corrected for protein concentrations. Within the d-amphetamine 
treated group the increase in startle could be directly correlated 
with the number of receptors occupied for each animal tested r (5) = 
0.963, p < .001. The data also show that minimal occupation of 
alpha-1-adrenergic sites by the agonist is necessary to counteract a 
net decrease in startle normally observed in these test conditions 
(4,15). A significant correlation was also found between the increase 
in startle caused by either 25 or 50 ug of phenylephrine in both 
lesioned and non-lesioned animals and the 3H-prazosin binding sites 
occupied, r (16) = 0.50, p < 0.02. However, following the intrathecal 
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CHANGE IN RECEPTOR OCCUPATION 
(fmole/mg protein) 
FIGURE 3. Correlation between estimated receptor occupation of 
individual animals (washed minus unwashed) and percent startle 
increase (mean amplitude startle measured from 15 to 30 minutes 
post-infusion following lOOug d-amphetamine minus mean startle 
amplitude over the 14 minute pre-drug baseline).. 
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administration of saline no significant difference in binding was 
observed between the ’unwashed* (98.9 fmoles of 3H-prazosin bound) and 
’washed' (96.6 fmoles of 3H-prazosin bound) fractions when assayed at 
equivalent dilutions in the presence of 0.75 nM 3H-prazosin. 
Various doses of phenylephrine were tested for their effects on 
acoustic startle response one week following either 6-OHDA lesion or 
sham-lesion. In both lesioned and unlesioned animals there was a 
significant effect of varying the dose of phenylephrine on the 
acoustic startle response, F (3/36) = 6.18, p < .005 (Figure 4). 
Moreover, there was a significant difference between the increase in 
acoustic startle caused by the 12.5 ug dose of phenylephrine in 
lesioned vs sham animals, _t (1.0) = 3*31» p < .01, indicating that 
phenylephrine in a dose of 12.5 ug was able to induce a large increase 
in acoustic startle in lesioned rats but not in sham animals. 
The magnitude of the excitatory effect of phenylephrine in 
acoustic startle increased as a function of the time, after 6-OHDA 
administration, F (3.21) = 3*12, p < 0.05, this effect was linear over 
a time period from 3 days to 4 weeks, F lin (1,21) = 8.98, p < 0.01. 
An increase in the number of specific 3H-prazosin binding sites in 
animals lesioned with 6-OHDA at various time intervals (3 days, 1, 2, 
or 4 weeks) also occured (Table 2). A scatchard plot of data from 
4-week 6-OHDA lesioned and sham-lesioned animals is shown in Figure 5. 
This analysis indicated that the increase in specific 3H-prazosin 
binding observed 4 weeks after pretreatment with 6-OHDA could be 
attributed to an increase in the total number of binding sites (Bmax) 
without a significant change in the dissociation constant (KD). Table 
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FIGURE A. Mean change in startle amplitude (+S.E.M.) averaged 
from 15 to 30 minutes post-drug infusion minus the startle averaged 
over the 14 minute pre-drug period for three doses of phenylephrine 
and saline in both 1 week 6-OHM lesioned and sham-operated animals, 
n=6 at each point. 
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TABLE 2 
Dissociation constants (K_), receptor densities (B^ ) and phenyl¬ 
ephrine's ability to inhibit pHjprazosin (1 nM) binding (K^) of 
alpha-1-noradrenergic receptors in control and lesioned tissue at 
various time points. 
Scatchard plots of [^Hjprazosin binding (0.05-2.0 nM) were deter¬ 
mined from pooled tissue for each group at each time point. 
values were calculated from the equation: 
K^ic50/(nfree ”dloliean-d) 
IC^q values were obtained from inhibition curves. 5-8 rats at each 
particular treatment. 
Vehicle 6-OHDA 
kd ®max KiCnM) kd ^max Ki(nM) 
3 days 0.30 47.9 0.30 51.6 
1 week 0.37 44.2 2905 0.30 53.8 3271 
2 weeks 0.46 39.9 0.42 53.7 
4 weeks 0.38 43.5 4688 0.40 60.3 4511 
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3H-PRAZOSIN BOUND (fmole/mg protein) 
FIGURE 5. Scatchard analysis of [^Hjprazosin binding to rat lumbar 
spinal cord membranes from animals treated 4 weeks previously with 
either 6-OHDA or vehicle. B/F is the ratio of specific bound [^H]- 
prazosin to free [^H]prazosin. The slope of each individual plot 
gives an estimate of the equilibrium dissociation constant (Kp at 
25°C) and the intersection with the abcissa gives a measure of the 
total number of binding sites (Bmav). (Vehicle KD«0.38 nM, 
®max“^.5 fmol/mg protein; 6-OHDA Kd*0.40 nM, Rmax“60.3 fmol/mg 
protein). 
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2 presents the observed KD and Braax values in each of the 4 time point 
groups. The Ki values, coupled with constant KDs in sham vs. lesioned 
rats, indicates that the 6-OHDA lesion does not have a significant 
effect on receptor affinity. 
A correlation between the change observed in the maximal number 
of binding sites (lesioned vs. sham) at each of the four time points, 
and the mean percent change in startle following an intrathecal dose 
of 12.5 ug phenylephrine is shown in Figure 6. A high correlation was 
found between the increase in the number of 3H-prazosin binding sites 
and the magnitude of the startle increase, r (2) = 0.99, p < 0.01. 
An estimate for the number of receptors occupied was calculated 
by "washed" minus "unwashed" 3H-prazosin binding values (corrected for 
protein concentration) in animals exhibiting maximal behavioral 
changes in response to drug infusion. Comparing these numbers to the 
Bmax values obtained by Scatchard analysis of tissue from respective 
treatment groups gives the percentage of receptor occupied (Table 3)* 
Occupation of approximately 30$ of the total alpha-1-adrenoceptors is 
sufficient to produce a maximal increase in the startle response in 
both control and lesioned animals. 
Howe and Yaksh (29) have demonstrated that intrathecal 6-OHDA 
depletes lumbar cord levels of NE within 1 day following treatment, 
peaking at 2 weeks (98% depletion) and continuing for at least 4 weeks 
after lesion. In the present experiments, we examined the 
localization of intrathecal 6-OHDA induced depletions of 
norepinephrine at various levels of the neuraxis. Intrathecal 6-OHDA 
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CHANGE IN Bmax (6-OHDA-VEHICLE) 
(fmole/mg protein) 
FIGURE 6. Correlation between increases in receptor number (E^y) 
as described by Scatchard analysis and mean percent startle increase 
in response to 12.5ug of intrathecal phenylephrine, ((startle aver¬ 
aged from 15 to 30 minutes post-drug infusion minus startle averaged 
over a 14 minute pre-drug period) x 100). 
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TABLE 3 
Percentage of binding sites occupied in order to produce a significant 
increase in startle response over controls. 
Individual binding scores were computed for each animal and the mean 
score for each treatment point was then compared to the Bmax to get an 
estimate for the percentage of receptors occupied: 
(specific binding washed - specific binding unwashed) v , nn 
X lull 
Dmax 
n = 5 at each treatment point. 
Mean receptors Bmax Percentage 
occupied (fmol/ (fmol/mg receptors 
mg protein)protein) occupied 
6-OHDA pretreatment (12.5ug PE) 
Vehicle pretreatment(50 ug PE) 
No pretreatment (lOOug d-AMP) 
13.7 2.7 53.7 26% 
8.5 0.8 36.9 23% 
13.2 + 1.1 40.0 33% 
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lesions of the lumbar cord caused significant reductions in NE levels 
in the lumbar cord, t (16) = 9.85, p < 0.001, but not in the brain 
stem or cerebral cortex (Table 4). Within the spinal cord a gradient 
of NE depletion was found with greatest depletions in the lumbar and 
thoracic areas (96% depletion), and less in the more rostral cervical 
regions (3355). As previously reported (11), no significant 
alterations of 5_HT levels in the lumbar cord were observed following 
localized 6-0HDA injections (control = 218 + 25 ng/mg; lesion = 196 + 
19 ng/mg). 
The purpose of the present study was to evaluate how changes in 
alpha-1- adrenoceptor binding parameters could be correlated with 
changes in functional alpha-1-adrenoceptor transmission, by measuring 
the effects of alpha-1-agonists on a behavioral reflex. Consistent 
with the results of experiment 1, intrathecal administration of the 
alpha-1-adrenergic agonist phenylephrine or d- amphetamine increased 
the amplitude of the acoustic startle reflex (15). The excitatory 
effect of intrathecal amphetamine appears to be due to its actions 
within the spinal cord since supraspinal (intraventricular) 
administration of amphetamine in equivalent doses does not increase 
startle (Commissaris and Davis, unpublished). In addition, Yaksh and 
Rudy (70) have shown that radioactive substances of varing lipid 
solubility infused into the lumbar enlargement of the rate spinal cord 
remain localized in the region around the tip of the cathether with 
little caudal to rostral diffusion when measured from 4-60 min after 
infusion. In the present study the magnitude of alpha-1-agoni st 
induced increases in acoustic startle correlated positively, within 

33 
TABLE 4 
Alterations in rat CNS norepinephrine levels after intrathecal adminis¬ 
tration of 6-OHDA. 
Rats were infused intrathecally with 20ug of 6-OHDA in lOul 0.1% ascorbic 
acid, sacrificed 2 weeks later, and the brain and spinal cord regions 
dissected and stored at -70°C. Control rats were administered the same 
volumes of vehicle solution. KE levels were determined as described in 
the text. Values are mean ± S.E.M. of 9 animals. 
Region Norepinephrine levels 
(ng/g wet weight) 
Control Lesion A* 
Cortex 240 ± 19 228 ± 24 -5 
Brainstem 293 ± 11 286 ± 11 -2 
Lumbar spinal cord 103 ± 10 4 ± 1** -96 
**Significantly different from control. P<0.001. 
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animals, to the number of 3H-prazosin binding sites occupied by that 
agonist. Intrathecal administration of 6-OHDA caused a marked and 
selective decrease in spinal NE and an increase in the number of 
3H-prazosin binding sites with no change in their affinity. From 3 
days to 4 weeks after 6-OHDA the number of 3H-prazosin binding sites 
and the behavioral effects of phenylephrine increased linearly in a 
highly correlated fashion. Hence, under these conditions, changes in 
alpha-1-adrenoceptor number was closely associated with changes in 
functional alpha-1-adrenergic transmission. 
The increase in acoustic startle following denervation correlated 
with a change in the number of receptors without any change in the 
affinity for the ligand. Behavioral supersensitivity has also been 
found following denervation or prolonged receptor blockade, which can 
be correlated with changes in receptor number rather than receptor 
affinity (11,44). 
In summary, the present results document that a behavioral 
supersensitivity to an alpha-1 agonist produced by 6-OHDA is directly 
correlated with an increase in the number of alpha-1-adrenoceptors. 
Given the ability of this system to analyze supersensitivity leading 
to increased alpha-1 receptors and increased behavioral responsiveness 
it was then decided to test whether the opposite response could be 
observed and critically examined: the phenomenon of behavioral 
desensitization. 
Experiment _3: Alpha-1 adrenergic stimulation of acoustic startle in 
desensitized and normal animals: behavior and binding studies. 
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Previous biochemical and Dhysiological studies have shown that 
prolonged exposure of receptor sites to certain neurotransmitters or 
their agonists results in decreased responsiveness or desensitization 
to these substances (7,8,31,43,58). In a number of neurotransmitter 
systems, desensitization has been shown to be associated with 
decreases in the number of receptor sites as measured by radioligand 
binding techniques (7,31,^3,53,58). At a behavioral level, 
desensitization or tachyphylaxis has been frequently observed. 
However, a number of mechanisms could account for such decreases in 
behavioral responsivity. To determine whether behavioral 
densensitization is associated with a decrease in receptor density it 
is necessary to examine a system in which behavioral changes in drug 
responsivity are highly correlated with changes in receptor number. 
As has just been shown denervation supersensitivity to the excitatory 
effects of the alpha-1- agonist phenylephrine on the acoustic startle 
reflex is highly correlated with the number of 3H-prazosin binding 
sites in the lumbar spinal cord. Thus the effects of intrathecal 
phenylephrine on the acoustic startle reflex represents a specific 
method to probe alpha-1- adrenoceptor sensitivity which is correlated 
with receptor density. 
By exposing the animal to phenylephrine and then reintroducing it 
several hours later it was hoped that behavioral desensitization could 
be induced. Once induced, given the ease of analysis the acoustic 
startle system affords, it should be possible to observe whether or 
not a change in receptor density occurs. 
Testing Procedure. 
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One week following implantation the rats were divided into two 
groups which received either intrathecal saline or 50 ug of 
phenylephrine dissolved in 10 ul of saline (pH 7.4). Six hours later 
the animals were placed in the startle test cages and 5 min later a 
program began which gave startle-eliciting noise bursts every 20 sec 
for 14 min. This constituted the pre-drug baseline. Based on the 
average startle performance across this baseline period the two 
pretreatment groups were divided into two groups that had roughly 
comparable baselines creating a total of four groups. The rats were 
then removed from their cages and infused a second time with either 50 
ug phenylephrine (i.e., Groups SAL-PE and PE-PE) or saline (Groups 
SAL-SAL and PE-SAL) . Two additional groups of rats were infused with 
phenylephrine or saline without any prior saline infusion to assess 
the importance of this treatment. All animals were tested for 
acoustic startle at approximately the same time of day in order to 
eliminate any possible influence of diurnal variation in the 
behavioral response. Immediately following the final infusion animals 
were returned to their test cages and given noise bursts every 20 sec 
for 30 min. Previous work has shown PE’s maximal stimulatory effect 
occurs approximately 20 min following drug infusion. Therefore, the 
mean startle amplitude from 15 to 30 min after the drug infusion for 
each rat was compared with that rat’s mean pre-drug infusion score to 
determine the change in startle amplitude following treatment. 
As shown in Figure 7, intrathecal administration of 50 ug PE 
increased startle amplitude about 80% over the predrug baseline while 
saline treated animals showed the typical decline in startle amplitude 
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by about 40$ over the same test period, indicative of habituation 
under these test conditions (4). Animals infused with saline 6 hrs 
previously (Group SAL-PE) were not significantly different in their 
responses to intrathecal phenylephrine compared to their respective 
non-preinfused counterparts (Group "--PE"; p < .10). Animals 
preinfused with PE, however, were barely responsive to another PE 
infusion 6 hrs later, and significantly different in their response to 
PE compared to rats pre-inf used with saline, (Group SAL-PE vs. PE-PE: 
t (14) = 5.59, p < .001). The lack of effect of PE in these animals 
did not result from an elevation in their baselines produced by the 
earlier PE infusion. The effect of PE had dissipated by 6 hrs and in 
fact the baselines of Groups PE-PE and SAL-PE prior to their second 
infusion were essentially identical (data not shown). These results 
indicate marked desensitization following prior exposure to PE. 
To assess the specificity of desensitization, a similar 
experiment was done using the indirect alpha-1-agonist d-amphetamine 
(dAMP) as the test drug 6 hrs following phenylephrine. Intrathecal 
d-amphetamine has been shown to increase startle and this effect can 
be blocked by WB-4101 but not by haloperidol, cyproheptadine or 
propranolol, indicating that an alpha-1- adrenergic receptor is 
involved (4,15). Fig. 8 confirms this in showing that both 
phenylephrine or d-amphetamine increase startle when given 
intrathecally in unpretreated animals. Most importantly, however, 
d-amphetamine had little effect in animals pretreated with 
phenylephrine as indicated by a significant difference in the response 
to dAMP in rats pretreated with saline vs PE (SAL-dAMP vs. PE-dAMP; t 
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FIGURE 7. Mean percent change in startle amplitude following intra¬ 
thecal infusion of the test drugs: saline (SAL) or phenylephrine (PE). 
The test drugs were given with no pretreatment or 6 hours after 
intrathecal infusion of PE. Percent change in startle amplitude from 
15 to 30 minutes after the test drug with the mean startle amplitude 
over the 14 minute period prior to the test drug. 
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FIGURE 8. Mean percent change in startle to various test drugs 
(phenylephrine — PE; d-amphetamine — d-AMP; strychnine — STRY; 
or 5-methoxydimethyltryptamine — 5-MEO) after different pretreat¬ 
ments. Pretreatment 1 consisted of intrathecal infusion of PE 6 
hours prior to Pretreatment 2. Pretreatment 2 consisted of intra¬ 
thecal infusion of SAL, PE, or d-AMP 30 minutes prior to intrathecal 
infusion of the test drugs. Percent change in startle (iS.E.M.) was 
computed by comparing the mean 6tartle amplitude from 15 to 30 
minutes after the test drug with the mean startle amplitude over 
the 14 minute period prior to the test drug. 
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(16) = 4.41, p < .001). This indicates that cross tolerance occurred 
between phenylephrine and the indirectly acting alpha-1-adrenergic 
agonist d-amphetamine. 
To more fully test specificity, the PE-dAMP and the PE-PE rats 
were given a final intrathecal infusion of either strychnine 6.25 ug 
(STRY - a glycine antagonist) or 5-methoxy-N,N-dimethyltryptamine 50 
ug (5-MeoDMT - a 5~HT agonist). Both drugs have previously been found 
to increase acoustic startle when administered intrathecally to 
unpretreated rats (16,34). Fig. 8 shows that both drugs still 
increased startle in rats that were tolerant to d-amphetamine or PE (t 
(6) = 2.67, p < .05 for strychnine, t (10) = 2.60, p < .02 for 
5-MeoDMT). This indicates that the desensitizing effect of prior 
exposure to alpha-1-agonists did not generalize to drugs that act 
through glycine or 5~HT receptors. 
One possible explanation for the desensitization reported above 
is that the alpha-1-adrenergic receptors involved in the modulation of 
startle have decreased in number or undergone a conformational change 
following prior exposure to PE, rendering them less responsive in 
subsequent challenge tests. To evaluate this possibility Scatchard 
analysis of alpha-1-adrenoceptor sites and phenylephrine competition 
curves were performed on lumbar spinal cord tissue taken from other 
groups of animals 6 hrs following either intrathecal saline or 50 ug 
of intrathecal phenylephrine. 
At 6 hrs following 50 ug of intrathecal phenylephrine or saline 
infusion animals were killed by decapitation and a 2.5 cm section of 
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lumbar cord was dissected out, weighed and frozen for subsequent JH- 
prazosin assays. Animals were sacrificed at the same time of day that 
the behavioral experiments were run in order to minimize reported 
circadian variations of B values (32). Lumbar spinal cord tissues 
for each treatment group (5-6 rats) were pooled and homogenized in 
cold 1:200 (w/v) of Tris HC1 buffer (pH 7.4), centrifuged at 42,000 x 
g for 10 minutes, resuspended and centrifuged two additional times. 
Control experiments indicated that any phenylephrine remaining in the 
tissue was completely removed from the crude membrane preparations by 
these washing procedures. The resulting washed membrane pellets were 
resuspended in cold 1:40 (w/v) 50 mM Tris HC1 buffer (pH 8.0). 
Aliquots (0.8 ml) of this homogenate were incubated in the presence of 
ascorbic acid (0.1$) and varying concentrations of H- prazosin (0.05 
to 1.0 mM) (Amersham-Searle, S.A., 20.2 Ci/mM) and 0.05 M Tris HC1 
buffer (pH 8.0) to 1.0 ml total volume. Non-specific binding was 
assessed by the addition of 1 uM WB-4101. Quadruplicate sample and 
triplicate non-specific binding values were obtained for each 
3 
concentration of H- prazosin. Incubations were carried out at room 
temperature for 30 min. After incubation the samples were rapidly 
filtered through GF/B filters (Waltham Co., U.K.) under low vacuum. 
The filters were washed with three 6 ml aliquots of ice cold 50 mM 
Tris buffer (pH 7.4) and counted in a liquid scintillation counter in 
8 ml Econofluor (New England Nuclear). The maximum number of binding 
sites (B ) and apparent dissociation constant (Kn) were estimated by 
Scatchard analysis. Values were obtained from four separate 
experiments, each with 5-6 animals per treatment group. Protein 
concentrations were determined by the method of Lowry et al. (38). 
0 
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Pooled tissue from PE and saline pretreated animals were analyzed 
for ->ti- prazosin binding and its abililty to be displaced by the _in 
vitro addition of various concentrations of phenylephrine. Washed 
lumbar cord membranes were prepared as described above and incubated 
•3 
in the presence of 1 nM JH-prazosin and various concentrations of 
phenylephrine (1 x 10(— 3) M to 1 x 10(—6) M) in the presence or 
absence of 1 uM WB—4101. 
The Scatchard plot in Fig. 9 shows a decrease in the number of 
prazosin binding sites in animals pretreated with phenylephrine 6 hrs 
prior to sacrifice without a significant change in the affinity of the 
receptor for the antagonist (Saline: B = 56.5 fmols/mg protein, Kn 
IT13.X U 
= 0.57 nM vs Phenylephrine B = 43.9 fmoles/mg protein, Kn = 0.48 
max u 
nM). In addition, the Ki for phenylephrine was similar in PE 
pretreated (3.5 nM) and in saline pretreated (3-8 nM) animals (p < 
0.1), indicating no change in the affinity of binding sites for 
phenylephrine following agonist pretreatment. 
The purpose of the present study was to determine whether 
specific desensitization of alpha-1-receptors could be induced and 
observed in a behavioral paradigm: the acoustic startle response. 
Consistent with previous data, intrathecal administration of the 
alpha-1-adrenergic agonist phenylephrine or the indirect alpha-agonist 
d-amphetamine increased the amplitude of the acoustic startle response 
in animals receiving no pretreatment or an intrathecal saline 
pretreatment 6 hrs prior to startle testing. Such excitatory effects 
of intrathecal phenylephrine on startle can be blocked by systemic 
administration of the alpha-1-adrenergic antagonist WB-4101, but not 
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FIGURE 9. Scatchard analysis of [%]prazosin binding to rat lumbar 
spinal cord membranes from animals treated 6 hours previously with 
either intrathecal saline or 50ug of intrathecal phenylephrine 
dissolved in saline. B/F is the ratio of specifically bound [%]- 
prazosin to free [^Hjprazosin. The slope of each individual plot 
gives an estimate of the equilibrium dissociation constant (Kp at 
25°C). The intersection aith the abcissa gives a measure of the total 
number of binding sites (Bmax). The post saline K^= 0.57 nM, 
Broav- 56.5 fmoles/mg protein. The post PE Kp* 0.48 nM, Bffiax=43.9 
fmoles/mg protein. 
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by haloperidol, propranolol, yohimbine or cyproheptadine (4,15). This 
behavioral effect of phenylephrine represents, therefore, a specific 
method to probe alpha-1-adrenergic receptor sensitivity. In the 
present study however, pretreatment of animals with intrathecal 
phenylephrine dramatically decreased the normal stimulatory effect of 
an alpha-1-agonist infused 6 hrs later. These same animals, 
unresponsive to either phenylephrine or d-amphetamine, were still able 
to respond to intrathecal infusion of the glycine antagonist 
strychnine or the serotonin agonist 5-MeoDMT with significant 
increases in startle magnitude. These results satisfy, therefore, 
Waud’s criteria for distinguishing specific from non-specific 
desensitization (66). Three representative drugs (an alpha-1-agonist, 
a serotonin agonist and a glycine antagonist) produce the same 
response (increase in startle magnitude) by interacting with three 
different receptors while desensitization of the response to one 
(alpha-1-agonist) is not accompanied by desensitization to the other 
two. 
v 
Using H- prazosin as a marker for alpha-1-adrenergic binding 
sites it was shown, through Scatchard analysis, that the number of 
alpha-1-adrenergic binding sites was decreased 6 hrs following an 
intrathecal phenylephrine infusion without a change in the binding 
sites' affinity for the antagonist. In addition, agonist affinity was 
also unchanged as observed through the use of phenylephrine 
competition curves. 
GENERAL DISCUSSION 
V 
44 
The results of these experiments may be summarized as follows: 
Experiment 1_: showed that both serotonin and its agonist 
5-Methoxy DMT and norepinephrine and its alpha-1 agonist phenylephrine 
produced dose dependent increases in acoustic startle amplitude when 
administered directly onto the lumbar spinal cord. These effects were 
specific as they were blocked by their respective antagonists but not 
by antagonists of other transmitter systems. Dopamine and its agonist 
apomorphine were without effect on acoustic startle when administered 
intrathecally. 
Experiment 2: demonstrated that intrathecal administration of 
6-OHDA caused a marked and selective depletion of spinal NE with a 
concomitant increase in the number of 3H-prazosin binding sites with 
no change in their affinity. The behavioral effects of phenylephrine 
increased linearly in a highly correlated fashion with the number of 
3H-prazosin binding sites. Changes in alpha-1-adrenoceptor number was 
closely associated with changes in functional alpha-1 adrenergic 
transmission. In addition, a high correlation was found between 
receptor occupation and behavioral response to intrathecal 
d-amphetami ne. 
Experiment 3: showed that specific 
receptors could be induced and observed 
response paradigm. The desensitization 
phenylephrine was specific in that only 
phenylephrine and the indirect alpha-1 a 
desensitization to alpha-1 
in the acoustic startle 
induced by pretreatment with 
the direct alpha-1 agonist 
gonist d-amphetamine no longer 
proved efficacious in increasing startle amplitude while 5~MeODMT and 

45 
strychnine were still able to markedly augment acoustic startle 
amplitude. This desensitization was accompanied by a decrease in 
alpha-1 adrenergic binding sites without an observed change in 
receptor affinity. 
The way in which serotonin, norepinephrine and their agonists 
enhance the startle response is most probably similar to that proposed 
for the modulation of cell firing in the facial motor nucleus (12). On 
these motor cells, iontophoretic administration of 5~HT or NE does not 
have any direct excitatory effects. However, such treatment does 
markedly increase excitation that is produced by electrical 
stimulation of afferents to these cells. Essentially identical 
modulatory effects of NE and 5-HT have also been reported for lower 
motor neurons in the spinal cord (18). In the case of acoustic 
startle, therefore, intrathecal administration of 5~HT or NE or their 
agonists should amplify the effects of the afferent volley to these 
neurons initiated by presentation of the acoustic startle stimulus. 
This interpretation is also consistent with the finding that 5~HT and 
NE increase the amplitude of spinal reflexes in spinal or decerebrate 
animals (2,3»40,52). 
These effects also involve specific agonist receptor interactions 
as 5-HT antagonists block the effects of 5-MeODMT but not PE and 
alpha-1 antagonists block PE's effect but not 5-MeODMT. It is 
interesting to note that in the present study propranolol did not 
block the excitatory effect of intrathecal 5-MeODMT while previous 
work has shown that systemic pretreatment with propranolol antagonizes 
the increased startle caused by systemically administered 5-MeODMT 
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(16). Propranolol has also been shown to block the syndrome caused by 
systemically administered 5-MeODMT or 5~HT precursors and a monoamine 
oxidase inhbiitor (25). Microiontophoretic work has shown, however, 
that propranolol is ineffective in blocking the facilitation of the 
facial motor nucleus caused by direct application of 5-HT or 5~HT 
agonists (G.K. Aghajanian, personal communicati on). It would seem, 
therefore, that the antagonism caused by propranolol found in some 
studies may be a secondary effect related to systemic administration 
of both propranolol and 5-MeODMT. 
In contrast to 5~HT and NE, neither DA nor the DA agonist 
apomorphine increased acoustic startle when given intrathecally. This 
is particularly interesting, since apomorphine is known to increase 
both acoustic and tactile startle when given systemically (14,24), and 
this effect can be blocked by either the DA antagonist, haloperidol 
(14) or the alpha-1 antagonist phenoxybenzamine (35). Perhaps 
apomorphine increases startle by acting through a DA receptor in the 
brain which is then expressed by release of NE in the spinal cord. 
This hypothesis could be tested by seeing whether intrathecal NE 
antagonists would block the effects of systemic apomorphine. In fact, 
the present results open up the possibility that a variety of drug or 
environment manipulations that increase startle (e.g., sensitization 
to background noise, potentiation due to prior conditioning) might be 
expressed by release of 5~HT and/or NE into the spinal cord. Again, 
the technique of administering intrathecal antagonists could be used 
to test this directly. 
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The second group of experiments allowed the information gathered 
in the first series to be applied in an effort to more clearly 
understand the role of receptors and the drug-receptor complex in 
mediating specific behavior. It offered a number of opportunities to 
determine the relationship between the degree of receptor occupation 
and behavioral output. Since in these studies, in vitro membrane 
preparation was required, the true degree of in vivo receptor 
occupation could not be determined. During homogenization and 
incubation, drug which was not initially bound to receptors in vivo 
could compete for binding sites in the _in vitro assay. However, our 
'washed' minus 'unwashed' procedure does give an estimate for the 
raaximimum possible drug occupation of binding sites in the spinal cord 
membrane preparation. In each case, the percentage of 
alpha-1-adrenergic binding sites estimated to be occupied in animals 
exhibiting full potentiation of startle was about 30%. This figure 
was calculated when, either d- amphetamine or phenylephrine was used to 
increase startle. It also occurred in animals treated with 6-OHDA. 
Moreover, the Ki values for phenylephrine in lesioned and non-lesioned 
animals were similar, despite the large increase in receptor number 
after 6-OHDA treatment. Thus, the ability of phenylephrine to 
displace 3H-prazosin in _in vitro preparations of tissue from lesioned 
and non-lesioned animals was .constant. These data support the concept 
of 'spare receptors', in which only a fraction of the total number of 
receptors need to be occupied to give a full biological effect, 
consistent with data in other transmitter systems. Thus Paul et al., 
(48) has shown that a 30% occupation of benzodiazepine binding sites 
was sufficient to protect against drug induced seizures in mice. 
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Venter (64) found that only 10$ of cardiac beta receptors were needed 
to provide the full inotropic and cyclic AMP responses elicited by 
isoproterenol. Furchgott (23) using irreversible alpha adrenergic 
receptor antagonists found that more alpha receptors existed than were 
required for complete tissue activation in certain peripheral 
systems. 
In the present experiments, the magnitude of startle facilitation 
produced by a rather low dose of phenylephrine 4 weeks after 6-OHDA 
was actually higher than the maximal degree of facilitation seen after 
any dose in normal rats. Functionally, therefore, denervation 
resulted in an increase in the efficacy of phenylephrine along with an 
increase in potency. For example, in normal rats, the maximal startle 
increase caused by intrathecal phenylephrine was about 100$ above 
baseline even at the highest doses tested. In contrast, a dose of only 
12.5 ug increased startle by about 160$ in rats treated with 6-OHDA 4 
weeks earlier. 
There may be several reasons why higher doses of phenylephrine 
are not able to increase startle above about 100$ in normal rats. One 
possibility is that high doses were observed to elicit behaviors such 
as twitching and panting which may compete with the expression of the 
startle response. Thus, at high doses, these behaviors may subtract 
from the increase in startle expected. However, if these competing 
behaviors are not due to specific occupation of alpha-1-receptor 
sites, then one should not expect supersensitivity of these behaviors 
to develop following alpha-1-receptor site proliferation. Equivalent 
receptor occupancy in normal and 6-OHDA treated rats would result in a 
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greater absolute number of binding sites occupied by phenylephrine in 
denervated rats. Since the magnitude of startle change is directly 
related to the absolute number of alpha-1-binding sites, then a low 
dose of phenylephrine could result in a large (supranormal) increase 
in startle without eliciting incompatable behaviors. 
Another possibility to explain the lack of large doses of 
agonists in bringing out maximal behavioral changes is the phenomenon 
of receptor desensitization, involving changes in receptor recognition 
sites (28), and/or coupling steps beyond the receptor (21,22). Such 
desensitization processes are both time and dose dependent (22). Thus 
the inability to see large changes in startle following high doses of 
phenylephrine could result from desensitization. In 6-OHDA-treated 
rats, comparable numbers of receptors could be occupied by lower and 
hence less desensitizing doses of phenylephrine. 
The results of the third series of experiments do indeed show 
that desensitization can occur in intrathecally implanted animals and 
that this desensitization does involve changes in the number of 
reeptor recognition sites. These results support the work of others 
who have shown decrease in receptor number to accompany 
desensitization. Kababian et al. (31) working with the rat pineal 
beta-adrenergic-receptor, observed rapid subsensitivity that developed 
within hours and which correlated with progressively fewer 
beta-adrenergic-binding sites. Mickey et al. (43) studying 
catecholamine tolerance in the purified frog erythrocyte system, also 
found a correlation between desensitization and declining 
beta-adrenergic-receptor binding. These workers hypothesized that a 
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reduction in receptor binding is a major mechanism in the induction of 
desensitization to catecholamines. As in our study, receptor affinity 
for either agonist or antagonist was reported to be unchanged. Thus 
it appears that decrease in receptor number can occur in desensitized 
systems. However, in our studies, only a small absolute decrease in 
receptor binding density (22%) accompanied the complete 
desensitization of the behavioral resonse to phenylephrine. 
Experiment two showed that occupation of a minimum number of alpha-1 
adrenoceptor sites by the agonist is necessary to produce a net 
increase in the startle response. It is therefore possible that only 
a small decrease in receptor density could result in a sub-threshold 
activation of alpha-1 adrenoceptors for changing startle. Thus small 
decreases in receptor number could result in desensitization of the 
behavioral response, as observed in the present study. However, it is 
also possible that, in addition to changes in receptor density, 
coupling steps beyond the receptor may be involved in the 
desensitization processes (22). Such possibilities are currently 
under investigation. From the present study, however, it is clear 
that the ability to study behavior, pharmacology and biochemistry in 
the acoustic startle system makes it a powerful tool in the study of 
receptor mechanisms and other aspects of central nervous system 
plastici ty. 
V 
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